Lataa...
The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma
Children with high-risk and recurrent neuroblastoma have poor survival rates, and novel therapies are needed. Many cancer cells have been found to preferentially employ the glycolytic pathway for energy generation, even in the presence of oxygen. 3-BrOP is a novel inhibitor of glycolysis, and has de...
Tallennettuna:
| Julkaisussa: | Invest New Drugs |
|---|---|
| Päätekijät: | , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4831635/ https://ncbi.nlm.nih.gov/pubmed/20890785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9551-y |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|